CD276 and neoplasm: Clinically, B7‐H3 exhibits low expression in normal tissues while high expression in tumor tissues, which established it as a tumor‐associated antigen and a pivotal therapeutic target in oncology, leading to the assessment of B7‐H3 therapeutic antibodies in preclinical and Phase I–II clinical trials [5, 6, 7, 8].